ADAM17 and type 2 diabetes mellitus: Moreover, low-dose Pioglitazone (PIO), a peroxisome proliferator-activated receptor (PPAR)γ agonist, reduced ADAM17 enzymatic activity in human skeletal muscle, and that these effects were associated with an improvement in glyco-metabolic control and inflammatory state in type 2 diabetes [33].